← All forecasts · November 2–6

MKSI / FQ3 2026 (quarter ended 2026-09-30)

MKS Inc.

Reported: Nov 4, 2026

Forecast published

Opus 5.5 High in Shortcut

Review incomplete

Shortcut

3.80

Normalized diluted EPS

+4.0% vs Street

Off by $0.38 per share

Street

3.65

Normalized diluted EPS

November 1 consensus snapshot

Off by $0.53 per share

Real

4.18

Reported normalized EPS

Shortcut win

Reported result · Nov 4 ↗ · Provider normalized EPS 4.18 matches issuer non-GAAP diluted EPS 4.18.

USD per diluted ordinary/common share. Comparisons use unrounded estimates.

Model download

Explore the assumptions and calculations behind the forecast. This is the agent’s original workbook. Its review didn’t finish, so it hasn’t been checked or repaired.

Shortcut’s reasoning.

Guidance (5-Aug-26): revenue $1,350M ±$40M, non-GAAP EPS $3.58 ±$0.31; MKS beat its own EPS midpoint in all six quarters 1Q25–2Q26 (avg +$0.26) and revenue midpoint by ~$40M on average. Model assumes a smaller ~$25M revenue beat — segment build VSD +18% / PSD +5% / MSD +8.8% Q/Q product growth, cross-checked to end markets (semi +$12M, SI +$5M vs guide; E&P balancing at ~+$8M) — at 47.1% GM and $282M non-GAAP opex.

Mechanical share-count tailwind: guidance used 71.8M non-GAAP diluted shares (implies ~$419 avg price); actual 3Q26 average close was $295.41, so convert dilution net of capped calls falls to ~1.8M and non-GAAP diluted shares to ~69.98M (≈ +$0.10 EPS vs guidance basis). Model calibrates to reported 1Q26/2Q26 capped-call offsets within 0.02M.

Peer Sept-quarter prints were strong: Lam +22% Q/Q record revenue, KLA beat midpoint, UCT +18% Q/Q, Entegris +25% Y/Y, TTM +60% Y/Y with 2.13 book-to-bill — supports semi and E&P at/above guidance; the 3Q26 stock slump was sector/valuation-driven (no company pre-announcement).

Downside tested: parts shortages (Lam/Ichor), 50–80bp GM drag from Penang/Guangzhou ramps, mix (VSD, chemistry equipment), lower palladium pass-through and weaker EUR; a guide-midpoint outcome with 69.98M shares still gives ~$3.67.

Frozen consensus $3.65 (13 estimates) sits only $0.07 above the guidance midpoint; estimate $3.80 (+4%). Starting P(beat) 0.874 (large-cap prior 0.78, 6/6 beats) trimmed to 0.85 for model and supply risk.

On the record.

Reporting period
FQ3 2026 (quarter ended 2026-09-30)
Reporting basis
non-GAAP (consensus data 'normalized') diluted EPS per common share, USD — MKS non-GAAP net earnings / non-GAAP weighted diluted shares (net of convertible capped calls)
Consensus snapshot
November 1, 2026
Model / effort
Opus 5.5 · High effort
Workbook
Original workbook · review incomplete
Record history
Forecast generated
Nov 1, 2026 at 10:25 PM PST
First posted
Nov 2, 2026 at 4:10 PM PST
Result checked
Nov 6, 2026 at 1:55 AM PST
Result basis

Provider normalized EPS 4.18 matches issuer non-GAAP diluted EPS 4.18. All six frozen normalized historical EPS values match. Official release dated Nov 4; fresh provider panel labels report Nov 5. The issuer release date is shown; the provider date is retained separately.